Citadel Advisors
EPRX

Citadel Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Citadel Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
502,011
+271,835
+118% +$1.87M ﹤0.01% 5499
2026
Q1 		$1.67M Buy
+230,176
New +$1.85M ﹤0.01% 6489
2025
Q3 		– Sell
-18,236
Closed -$108K – 14371
2025
Q2 		$108K Buy
18,236
+6,182
+51% +$23.7K ﹤0.01% 11278
2025
Q1 		$39.4K Buy
+12,054
New +$41.6K ﹤0.01% 12553

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citadel Advisors's EPRX Position: Q2 2026 in Review

Citadel Advisors increased its Eupraxia Pharmaceuticals (EPRX) stake by 118% in Q2 2026, buying an estimated $1.87M and bringing the position to 502,011 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #5499.

Citadel Advisors first reported a position in EPRX in Q1 2025 and has held it in 4 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Citadel Advisors held 502,011 shares of Eupraxia Pharmaceuticals worth $3.32M as of Q2 2026.
  • Citadel Advisors bought 271,835 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $1.87M.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5499 holding.
  • Citadel Advisors first reported a position in Eupraxia Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.